Precigen (NASDAQ:PGEN) CEO Helen Sabzevari Sells 346,836 Shares

Precigen, Inc. (NASDAQ:PGEN) CEO Helen Sabzevari sold 346,836 shares of Precigen stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $5.89, for a total transaction of $2,042,864.04. Following the sale, the chief executive officer owned 3,768,872 shares in the company, valued at approximately $22,198,656.08. This trade represents a 8.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Sabzevari also recently made the following trade(s):

• On Thursday, May 28th, Helen Sabzevari sold 119,250 shares of Precigen stock. The stock was sold at an average price of $4.36, for a total transaction of $519,930.00.

Precigen Price Performance

PGEN traded down $0.45 during midday trading on Wednesday, reaching $5.25. 7,446,304 shares of the company’s stock were exchanged, compared to its average volume of 4,558,847. The company has a quick ratio of 4.12, a current ratio of 4.82 and a debt-to-equity ratio of 4.62. The business has a 50-day simple moving average of $4.40 and a two-hundred day simple moving average of $4.21. The firm has a market capitalization of $1.87 billion, a price-to-earnings ratio of -4.45 and a beta of 1.06. Precigen, Inc. has a one year low of $1.45 and a one year high of $6.04.

Precigen (NASDAQ:PGEN) last released its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.01. The company had revenue of $23.25 million for the quarter, compared to analyst estimates of $20.81 million. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%. As a group, research analysts predict that Precigen, Inc. will post -0.02 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Wall Street Zen downgraded shares of Precigen from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Zacks Research raised shares of Precigen from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Citizens Jmp boosted their price target on shares of Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a research report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a research note on Tuesday, April 21st. Finally, Citigroup reissued an “outperform” rating on shares of Precigen in a report on Thursday, May 14th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Precigen currently has an average rating of “Hold” and an average price target of $12.50.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Boxer Capital Management LLC acquired a new position in Precigen during the 3rd quarter worth $2,796,000. Occam Crest Management LP increased its position in shares of Precigen by 29.6% in the 4th quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company’s stock valued at $14,637,000 after buying an additional 799,339 shares in the last quarter. Investment Insight Wealth Management LLC acquired a new stake in shares of Precigen during the fourth quarter worth about $443,000. UBS Group AG raised its holdings in Precigen by 41.4% during the 4th quarter. UBS Group AG now owns 891,428 shares of the biotechnology company’s stock worth $3,726,000 after buying an additional 260,824 shares during the period. Finally, Impala Asset Management LLC bought a new stake in Precigen in the 4th quarter valued at $690,000. 33.51% of the stock is owned by institutional investors.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.